First treatment for all patients with DMD approved in UK

We are delighted to welcome the news that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved vamorolone (sold under the brand name Agamree) for the treatment of Duchenne muscular dystrophy (DMD) in patients aged four years and older.

This is the first treatment approved for all people with DMD, irrespective of their underlying mutation and ambulatory (walking) status. This is a key milestone towards access to vamorolone for patients and families in the UK.

Alex Johnson OBE and Emily Reuben OBE said: "We are delighted that the first drug developed to benefit everyone with Duchenne has been approved in the UK. When our sons were diagnosed with Duchenne, we were told that steroids would keep them independently mobile for longer. But with harmful side effects. We didn't think this was good enough, and invested in finding better treatments. For it now to be available in the UK to treat DMD is proof that we can find better treatments for Duchenne and change things."